# A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE

> **NCT03312907** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 292 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Belimumab
- **DRUG:** Rituximab
- **DRUG:** Rituximab-placebo
- **DRUG:** Standard therapy (Including Immunosuppressants)
- **DRUG:** Standard therapy (Excluding Immunosuppressants)
- **DRUG:** Steroid Taper

## Key facts

- **NCT ID:** NCT03312907
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-01
- **Primary completion:** 2020-05-29
- **Final completion:** 2021-07-07
- **Target enrollment:** 292 (ACTUAL)
- **Last updated:** 2025-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03312907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03312907, "A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03312907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*